Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.96 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.96 |
| ▸ | GAA known ✓ | P10253 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909845 | 0.98 | HSD17B10 (1.00) | GABRA5GABRB2HSD17B10LMNANOS1 | |
| SCHEMBL9864403 | 0.96 | HSD17B10 (0.96) | GABRA5GABRB2HSD17B10LMNANOS1 | |
| Methyl Alcohol SCHEMBL10946415 | 0.94 | HSD17B10 (0.93) | GABRA5GABRB2HSD17B10LMNANOS1 | |
| Acetic Acid SCHEMBL27742442 | 0.93 | HSD17B10 (0.89) | GABRA5GABRB2HSD17B10LMNANOS1 | |
| Hydrochloric Acid SCHEMBL11278622 | 0.83 | GABRA5 (0.68) | GABRA5GABRB2HSD17B10NOS1GAA | |
| SCHEMBL28100058 | 0.83 | GABRA5 (0.71) | GABRA5GABRB2HSD17B10GAAALDH1A1 | |
| SCHEMBL7845357 | 0.83 | GABRA5 (0.71) | GABRA5GABRB2HSD17B10GAAALDH1A1 | |
| SCHEMBL1797901 | 0.82 | GABRA5 (0.72) | GABRA5GABRB2HSD17B10LMNANOS1 | |
| SCHEMBL3736516 | 0.81 | GABRA5 (0.70) | GABRA5GABRB2HSD17B10NOS1GAA | |
| SCHEMBL17492250 | 0.81 | GABRA5 (0.70) | GABRA5GABRB2HSD17B10NOS1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109438385-A | The preparation method of high-purity 2- amino -4- thiazolyl acetic acid | 山东金城医药化工有限公司 | 2019-03-08 | — | — | CN | claimed |
| CN-101648961-B | Method and equipment for preparing cefotiam hydrochloride | HARBIN PHARMACEUTICAL GROUP CO LTD GENERAL PHARMACEUTICAL FACTORY | 2011-06-29 | — | — | CN | claimed |
| EP-0034340-B1 | PROCESS FOR THE PRODUCTION OF (2-AMINO-THIAZOL-4-YL) ACETIC ACID HYDROCHLORIDE | LONZA AG (CH) | 1984-01-04 | — | — | EP | claimed |
| US-4391979-A | Process for the preparation of (2-amino-thiazol-4yl)-acetic acid hydrochloride | LONZA LTD. (CH) | 1983-07-05 | — | — | US | claimed |
| CN-113773274-A | Recrystallization method of mirabegron alpha crystal form raw material | 石药集团中奇制药技术（石家庄）有限公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-108299469-B | Preparation method of cefotiam hydrochloride | 重庆常捷医药有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-109438385-A | The preparation method of high-purity 2- amino -4- thiazolyl acetic acid | 山东金城医药化工有限公司 | 2019-03-08 | — | — | CN | disclosed |
| WO-2014132270-A2 | PROCESS FOR THE PREPARATION OF 2-(2-AMINOTHIAZOL-4-YL)-N-[4-(2-{[(2R)-2-HYDROXY-2-PHENYL ETHYL]AMINO}ETHYL)PHENYL]ACETAMIDE MONOHYDROCHLORIDE, ITS INTERMEDIATES AND POLYMORPH THEREOF | MSN LABORATORIES LIMITED (IN) | 2014-09-04 | — | — | WO | disclosed |
| CN-103570745-A | Preparation method of cefotiam hydrochloride lactone | HARBIN PHARMACEUTICAL GROUP CO LTD GENERAL PHARMACEUTICAL FACTORY | 2014-02-12 | — | — | CN | disclosed |
| CN-101948446-B | Method for preparing 2-aminothiazol-4-ylacetic acid hydrochloride | JIANGSU HUAXU PHARMACEUTICAL CO LTD | 2013-05-15 | — | — | CN | disclosed |
| CN-101948446-B | Method for preparing 2-aminothiazol-4-ylacetic acid hydrochloride | JIANGSU HUAXU PHARMACEUTICAL CO LTD | 2013-05-15 | — | — | CN | disclosed |
| CN-102827099-A | Method for synthesis of 2-(2-aminothiazol-4-yl)acetic acid hydrochloride | HARBIN HENGYUN SCIENCE AND TECHNOLOGY DEV CO LTD | 2012-12-19 | — | — | CN | disclosed |
| EP-0093548-A2 | Cephalosporin derivatives | Takeda Chemical Industries, Ltd. (JP) | 1983-11-09 | — | — | EP | disclosed |
| US-4391979-A | Process for the preparation of (2-amino-thiazol-4yl)-acetic acid hydrochloride | LONZA LTD. (CH) | 1983-07-05 | — | — | US | disclosed |
| US-4391979-A | Process for the preparation of (2-amino-thiazol-4yl)-acetic acid hydrochloride | LONZA LTD. (CH) | 1983-07-05 | — | — | US | disclosed |
| US-4391979-A | Process for the preparation of (2-amino-thiazol-4yl)-acetic acid hydrochloride | LONZA LTD. (CH) | 1983-07-05 | — | — | US | disclosed |
| US-4379924-A | Cephalosporin derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1983-04-12 | — | — | US | disclosed |
| EP-0034340-A1 | Process for the production of (2-amino-thiazol-4-yl) acetic acid hydrochloride | LONZA AG (CH) | 1981-08-26 | — | — | EP | disclosed |
| US-4254260-A | 3-Substituted-7-substituted alkanamido-3-cephem-4-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-03-03 | — | — | US | disclosed |
| US-4080498-A | ANTIBIOTICS, BACTERICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1978-03-21 | — | — | US | disclosed |